Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
(-)-Cytisine
150
CHF
CHF 150.00
In stock
CDX-C0228-M100100 mgCHF 150.00
CDX-C0228-M500500 mgCHF 393.00
CDX-C0228-G0055 gCHF 1'154.00
| Product Details | |
|---|---|
| Synonyms | NSC 407282; BRN 0083882; Baptitoxine; Sophorine; (1S,5R)-3,4,5,6-tetrahydro-1H-1,5-methanopyrido[1,2-a][1,5]diazocin-8(2H)-one |
| Product Type | Chemical |
| Properties | |
| Formula | C11H14N2O |
| MW | 190.2 |
| CAS | 485-35-8 |
| RTECS | HA4025000 |
| Source/Host Chemicals | Synthetic. |
| Purity Chemicals | ≥99% (CHN) |
| Appearance | Light yellow powder/crystals. |
| Solubility | Soluble in toluene. |
| Identity | Determined by NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | ANJTVLIZGCUXLD-DTWKUNHWSA-N |
| Smiles | O=C1C=CC=C2[C@@H]3CNCC(C3)CN12 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
Pyridine-like alkaloid. Nicotine agonist. Potent agonist at α3β4 and α7 nicotinic acetylcholine receptors and partial agonist at α4β2 nicotinic acetylcholine receptors. Shows analgesic, antihypertensive and inotropic activities. Used for smoking cessation. Iron-chelator and hydroxyl radical scavanger. Has antidepressant properties. Used in forensics in novel surface molecular imprinting techniques.
Product References
(1) R.L. Papke & S.F. Heinemann; Mol. Pharmacol. 45, 142 (1994) | (2) B.W. Wenger, et al.; J. Pharmacol. Exp. Ther. 281, 905 (1997) | (3) B. Ferger, et al.; Eur. J. Pharmacol. 360, 155 (1998) | (4) Y.E. Slater, et al.; Neuropharmacology 44, 503 (2003) | (5) P. Tutka & W. Zatonski; Pharmacol. Rep. 58, 777 (2006) (Review) | (6) J.F. Etter, et al.; Drug Alcohol Depend. 92, 3 (2008) (Review) | (7) Y.F. Li, et al.; Auton. Neurosci. 154, 14 (2010) | (8) E.G. Perez, et al.; Nat. Prod. Rep. 29, 555 (2012) (Review)
Related Products
